Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers at Vall d'Hebron University, Medical Oncology Department release new data on cancer gene therapy
February 24th, 2009
Fresh data on cancer gene therapy are presented in the report 'Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.' "Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer. In vitro studies have shown that lapatinib enhances the effects of the monoclonal antibody trastuzumab suggesting partially non-overlapping mechanisms of action," scientists in Barcelona, Spain report. "To dissect these mechanisms, we have studied the effects of lapatinib and trastuzumab on receptor...
Source: Cancer Weekly (2009-02-24)
|
